Medical Doctor Program year 2022 Reported 2020–2022 Source: CMS Open Payments, 2026 publication

Mark Sundahl

Psychiatry Kansas City, MO Medical Doctor

NPI 1194189555 CMS profile 8161245

4801 E Linwood Blvd, Kansas City, MO 64128

Open in the dashboard

General payments

$2,902

199 records reported · program years 2020–2022

Research payments

$0

Paid to them · None reported · program years 2020–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Mark Sundahl of Kansas City, MO is reported in the CMS Open Payments database as having received $2,902 across 199 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $281 16
2021 General $1,852 135
2020 General $769 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Sundahl
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Mark Sundahl were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Mark Sundahl Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $769 $119 $36–$372 $114
2021 $1,852 $143 $43–$576 $132
2022 $281 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2020–2022
  1. Otsuka America Pharmaceutical, Inc. $461 24 payments
  2. AbbVie, Inc. $389 22 payments
  3. ITI, Inc. $315 31 payments
  4. Vanda Pharmaceuticals Inc. $238 10 payments
  5. Lundbeck LLC $229 17 payments
  6. Neurocrine Biosciences, Inc. $187 12 payments
  7. Eisai Inc. $140 9 payments
  8. Avanir Pharmaceuticals, Inc. $99 5 payments
  9. Biogen, Inc. $94 5 payments
  10. Neos Therapeutics, LP $93 6 payments
  11. Other $657 58 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2022
  1. Food and Beverage $2,902 199 payments
Products named General payments · program years 2020–2022
  1. VRAYLAR $389 22 payments
  2. CAPLYTA $315 31 payments
  3. ABILIFY MAINTENA $275 14 payments
  4. HETLIOZ $238 10 payments
  5. FANAPT $238 10 payments
  6. REXULTI Psychiatry $226 12 payments
  7. REXULTI Psychiatry $168 13 payments
  8. Dayvigo $140 9 payments
  9. INGREZZA $109 7 payments
  10. NUEDEXTA $99 5 payments
  11. Other $1,212 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

199 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record